ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 509,100 shares, an increase of 364.1% from the March 31st total of 109,700 shares. Based on an average daily trading volume, of 2,180,000 shares, the short-interest ratio is currently 0.2 days. Approximately 14.1% of the company’s shares are sold short.

Institutional Investors Weigh In On ZyVersa Therapeutics

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Virtu Financial LLC bought a new position in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned 1.08% of ZyVersa Therapeutics as of its most recent filing with the SEC. Institutional investors own 3.91% of the company’s stock.

ZyVersa Therapeutics Stock Down 2.0 %

Shares of ZVSA opened at $0.70 on Friday. ZyVersa Therapeutics has a twelve month low of $0.55 and a twelve month high of $6.70. The stock’s fifty day simple moving average is $0.86 and its 200 day simple moving average is $1.22.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.